{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T21:40:43Z","timestamp":1782337243327,"version":"3.54.5"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.critrevonc.2025.105095","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T07:45:46Z","timestamp":1766475946000},"page":"105095","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Chimeric antigen receptor T-cell therapy and immune effector cell-associated neurotoxicity syndrome: A meta-analysis"],"prefix":"10.1016","volume":"218","author":[{"given":"Ashwini","family":"Thirugnanam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karun","family":"Donthineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4217-9742","authenticated-orcid":false,"given":"Marco","family":"Mammi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie","family":"Hundel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Munteh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"D\u2019Amore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adomas","family":"Bunevicius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1636-0759","authenticated-orcid":false,"given":"Rania A.","family":"Mekary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.105095_bib1","article-title":"Assessing robustness against potential publication bias in coordinate based fMRI meta-analyses using the Fail-Safe N","author":"Acar","year":"2017","journal-title":"BioRxiv"},{"key":"10.1016\/j.critrevonc.2025.105095_bib2","doi-asserted-by":"crossref","DOI":"10.4065\/80.8.1087","article-title":"Non-Hodgkin lymphoma: diagnosis and treatment","author":"Ansell","year":"2005","journal-title":"Mayo Clin. Proc."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105095_bib3","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2352-3026(21)00060-0","article-title":"Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study","volume":"8","author":"Azoulay","year":"2021","journal-title":"Lancet Haematol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105095_bib4","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1096\/fasebj.11.8.9240966","article-title":"Hematological malignancies","volume":"11","author":"Brenner","year":"1997","journal-title":"FASEB J."},{"key":"10.1016\/j.critrevonc.2025.105095_bib5","first-page":"14651858","volume":"4","author":"Chandler","year":"2019"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105095_bib6","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105095_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2021.100826","article-title":"CAR T-cell therapy for B-cell lymphoma","volume":"46","author":"Denlinger","year":"2022","journal-title":"Curr. Probl. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105095_bib8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cct.2006.04.004","article-title":"Random-effects model for meta-analysis of clinical trials: an update","volume":"28","author":"DerSimonian","year":"2007","journal-title":"Contemp. Clin. Trials"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105095_bib9","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1358\/dot.2022.58.6.3378055","article-title":"Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma","volume":"58","author":"Deshpande","year":"2022","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.critrevonc.2025.105095_bib10","unstructured":"Forero-Forero, J.V., Lengerke-Diaz, P.A., Moreno-Cortes, E., Melody, M., Rahman, Z.A., Rosenthal, A.C., Kharfan-Dabaja, M.A., & Castro, J.E. (2021). Predictors and management of relapse to Axicabtagene Ciloleucel in patients with aggressive B-cell lymphoma. Hematology\/Oncology and Stem Cell Therapy."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105095_bib11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2025.105095_bib12","series-title":"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma","author":"Freedman","year":"2021"},{"issue":"18","key":"10.1016\/j.critrevonc.2025.105095_bib13","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1097\/BRS.0b013e3181b1c99f","article-title":"2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group","volume":"34","author":"Furlan","year":"2009","journal-title":"Spine"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105095_bib14","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jtct.2023.04.001","article-title":"Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy","volume":"29","author":"Gazeau","year":"2023","journal-title":"Transplant. Cell. Ther."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105095_bib15","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.1016\/S2352-3026(22)00225-3","article-title":"Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study","volume":"9","author":"Ghorashian","year":"2022","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.critrevonc.2025.105095_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2288-14-109","article-title":"Improving the error rates of the Begg and Mazumdar test for publication bias in fixed effects meta-analysis","volume":"14","author":"Gjerdevik","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105095_bib17","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jtct.2022.03.006","article-title":"Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: a systematic review","volume":"28","author":"Grant","year":"2022","journal-title":"Transplant. Cell. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105095_bib18","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/CCM.0000000000005149","article-title":"Critically ill patients treated for chimeric antigen receptor-related toxicity: a multicenter study","volume":"50","author":"Gutierrez","year":"2022","journal-title":"Crit. Care Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105095_bib19","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1177\/10781552221104816","article-title":"Use of long-term corticosteroids in patients treated with CAR T-cell therapy","volume":"29","author":"Hashmi","year":"2023","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.critrevonc.2025.105095_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102479","article-title":"Toxicities following CAR-T therapy for hematological malignancies","volume":"111","author":"Hernani","year":"2022","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105095_bib21","first-page":"112","article-title":"Immune effector cell\u2013associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes","volume":"23","author":"Holtzman","year":"2021","journal-title":"NeuroOncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105095_bib22","first-page":"1460","article-title":"Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy","volume":"109","author":"Jallouk","year":"2023","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105095_bib23","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3324\/haematol.2022.280805","article-title":"Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma","volume":"108","author":"Kwon","year":"2022","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105095_bib24","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13613-024-01247-9","article-title":"Features and outcomes of patients admitted to the ICU for chimeric antigen receptor T cell-related toxicity: a French multicentre cohort","volume":"14","author":"Le Cacheux","year":"2024","journal-title":"Ann. Intensive Care"},{"issue":"16","key":"10.1016\/j.critrevonc.2025.105095_bib25","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1182\/bloodadvances.2023009766","article-title":"Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma","volume":"7","author":"Lee","year":"2023","journal-title":"Blood Adv."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105095_bib26","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ymthe.2020.10.022","article-title":"Clinical perspective: treatment of aggressive B cell lymphomas with FDA-approved CAR-T cell therapies","volume":"29","author":"Leick","year":"2021","journal-title":"Mol. Ther."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105095_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010064","article-title":"Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis","volume":"12","author":"Liang","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105095_bib28","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2025.105095_bib29","doi-asserted-by":"crossref","first-page":"1399544","DOI":"10.3389\/fonc.2024.1399544","article-title":"Challenges and innovations in CAR-T cell therapy: a comprehensive analysis","volume":"14","author":"Luo","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105095_bib30","volume":"17","author":"Mavridis","year":"2014"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105095_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70070","article-title":"Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study","volume":"9","author":"Merz","year":"2025","journal-title":"HemaSphere"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105095_bib32","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nature Reviews Immunology"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105095_bib33","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid. Synth."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105095_bib34","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105095_bib35","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105095_bib36","article-title":"nccn. org\/professionals\/physician_gls\/PDF\/occult. pdf","author":"Network","year":"2008","journal-title":"NCCN Clin. Pract. Guidel. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105095_bib37","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1182\/bloodadvances.2023011896","article-title":"Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma","volume":"8","author":"Nie","year":"2024","journal-title":"Blood Adv."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105095_bib38","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.2174\/0113892010257212231001082741","article-title":"FDA-approved CAR T-cell Therapy: A Decade of Progress and Challenges","volume":"25","author":"Ong","year":"2024","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.critrevonc.2025.105095_bib39","first-page":"1","article-title":"Immuno-related cardio-vascular adverse events associated with immuno-oncological treatments: an under-estimated threat for cancer patients","author":"Panuccio","year":"2024","journal-title":"Basic Res. Cardiol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105095_bib40","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","article-title":"CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results","volume":"29","author":"Park","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2025.105095_bib41","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1182\/blood-2019-126208","article-title":"Easix and modified-Easix are early predictors of severe cytokine release syndrome and neurotoxicity in patients treated with chimeric antigen receptor T cells","volume":"134","author":"Pennisi","year":"2019","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.critrevonc.2025.105095_bib42","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","article-title":"Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells","volume":"5","author":"Pennisi","year":"2021","journal-title":"Blood Adv."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105095_bib43","doi-asserted-by":"crossref","first-page":"4996","DOI":"10.3390\/ijms25094996","article-title":"An assessment of the effectiveness and safety of chimeric antigen receptor T-cell therapy in multiple myeloma patients with relapsed or refractory disease: a systematic review and meta-analysis","volume":"25","author":"Pereira","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2025.105095_bib44","first-page":"1","article-title":"Chimeric antigen receptor T cell-related neurotoxicity: mechanisms, clinical presentation, and approach to treatment","volume":"21","author":"Rice","year":"2019","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.critrevonc.2025.105095_bib45","first-page":"335","volume":"389","author":"San-Miguel","year":"2023"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105095_bib46","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105095_bib47","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105095_bib48","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105095_bib49","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.hoc.2023.07.002","article-title":"Chimeric antigen receptor T-cells in indolent lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia","volume":"37","author":"Shah","year":"2023","journal-title":"Hematol. \/Oncol. Clin."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105095_bib50","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","article-title":"Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL","volume":"56","author":"Sheth","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.critrevonc.2025.105095_bib51","series-title":"Cancer facts & figures 2014","author":"Society","year":"2014"},{"key":"10.1016\/j.critrevonc.2025.105095_bib52","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"20","key":"10.1016\/j.critrevonc.2025.105095_bib53","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105095_bib54","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/ajh.27548","article-title":"Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B-Cell Lymphoma","volume":"100","author":"Thiruvengadam","year":"2025","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105095_bib55","first-page":"S355","volume":"30","author":"Tiwana","year":"2024","journal-title":"Transplant. Cell. Ther. Off. Publ. Am. Soc. Transplant. Cell. Ther."},{"issue":"25","key":"10.1016\/j.critrevonc.2025.105095_bib56","article-title":"Recommendations for quantifying the uncertainty in the summary intervention effect and estimating the between-study heterogeneity variance in random-effects meta-analysis","volume":"13","author":"Veroniki","year":"2015","journal-title":"Cochrane Methods"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105095_bib57","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","article-title":"Immunogenicity of CAR T cells in cancer therapy","volume":"18","author":"Wagner","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T12:28:40Z","timestamp":1770035320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825004834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":57,"alternative-id":["S1040842825004834"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105095","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric antigen receptor T-cell therapy and immune effector cell-associated neurotoxicity syndrome: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105095","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105095"}}